title: The HPV DNA virus hybrid capture assay: what is it--and where do we go from here?
abstract: The biotechnology that has made HPV DNA testing possible has the capacity to reduce the incidence of cervical carcinoma substantially, especially in the patients diagnosed with ambiguous low-grade lesions, such as ASC-US, on Pap smears. Reflex HPV DNA testing of thin layer preparations diagnosed as ASC-US, and in other certain instances as outlined by ASCCP, will play a major role in the management of abnormal cervical cytology. Other applications, such as possible primary screening, may in the future play a substantial role in cervical screening. These potential applications will require more in-depth study and research, and will ultimately have to stand the test of time.
authors.affiliation: Wayne State University School of Medicine, Cytopathology Department, Detroit Medical Center, Wayne State University, Detroit, USA.
authors.forename: John P
authors.initials: JP
authors.lastname: Vernick
authors.forename: Carmen K
authors.initials: CK
authors.lastname: Steigman
mesh_terms: D001709:Biotechnology; D004279:DNA, Viral / Q000032:analysis*; D004496:Education, Continuing; D005260:Female; D006801:Humans; D021141:Nucleic Acid Amplification Techniques; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis* / Q000821:virology; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000821:virology*; D014626:Vaginal Smears; D019562:Viral Load
chemical_list: D004279:DNA, Viral